This study reviewed the effectiveness of baricitinib (Olumiant) on the progression of structural joint damage (SJD) in patients with rheumatoid arthritis (RA).

The data showed that baricitinib may significantly help slow down SJD signs found in digital imaging in patients with non-existent or insufficient response to standard treatment drugs.

This study looked at the treatment of diabetic macular edema (DME) which has not responded to medical treatment with vitrectomy and dexamethasone (Ozurdex) implant. This study showed that this treatment improved the vision of patients with DME.

This study examined the effect of sarilumab (Kevzara) compared to adalimumab (Humira) on health-related quality of life (HRQoL) based on inflammatory marker levels in patients with rheumatoid arthritis (RA). 

The data showed that sarilumab has a higher effect on improving aspects of HRQoL in patients with higher levels of inflammation in the blood.

This study explored the effect of sitagliptin (Januvia) on the function of pancreas cells in patients with latent autoimmune diabetes in adults (LADA) receiving insulin therapy. The authors found that the combination of sitagliptin and insulin extends in time the ability of pancreas cells to produce insulin and improves the ability of the body to respond to insulin treatment.

This study looked at the effectiveness of treating diabetic macular edema (DME) with a treat and extend dosing regimen of aflibercept (Eylea). It found that after two years the number of injections was significantly reduced and their effectiveness was maintained.  

This study compared a combination of pioglitazone (Actos) and exenatide (Byetta) to insulin therapy for poorly controlled type 2 diabetes (T2D). It found that more patients receiving pioglitazone and exenatide achieved blood glucose control compared to those receiving insulin.

This study compared weekly semaglutide (Ozempic) and daily sitagliptin (Januvia) for type 2 diabetes (T2D) in an Asian population. It showed that patients treated with semaglutide had a greater improvement in T2D control and increased weight loss compared to those treated with sitagliptin.

This study looked at the effect of treatment with polyethylene glycol loxenatide (PEX168) alone in patients with poorly controlled type 2 diabetes (T2D). They found that PEX168 significantly improved blood glucose control in these patients.

This study looked at the use of sotagliflozin (Zynquista) in patients with poorly controlled type 2 diabetes (T2D) and chronic kidney disease (CKD). It found that patients taking sotagliflozin was associated with a lower risk of heart attack, stroke, or death. 

This study compared hybrid closed-loop (HCL) insulin delivery to an insulin pump or daily injections for adults with type 1 diabetes (T1D). It found that an HCL system led to better glucose control and a more positive experience of managing diabetes.